These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2557664)

  • 21. Prevention and treatment of CMV infection after allogeneic bone marrow transplant.
    Gluckman E; Traineau R; Devergie A; Esperou-Bourdeau H; Hirsch I
    Ann Hematol; 1992 Jun; 64 Suppl():A158-61. PubMed ID: 1322189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
    Takami A; Mochizuki K; Ito S; Sugimori C; Yamashita T; Asakura H; Okumura H; Nakao S
    Transplant Proc; 2007; 39(1):237-9. PubMed ID: 17275512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
    Ljungman P; Aschan J; Lewensohn-Fuchs I; Carlens S; Larsson K; Lönnqvist B; Mattsson J; Sparrelid E; Winiarski J; Ringdén O
    Transplantation; 1998 Nov; 66(10):1330-4. PubMed ID: 9846518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir.
    Brumble LM; Milstone AP; Loyd JE; Ely EW; Pierson RN; Gautam S; Dummer JS
    Chest; 2002 Feb; 121(2):407-14. PubMed ID: 11834650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
    Seu P; Winston DJ; Holt CD; Kaldas F; Busuttil RW
    Transplantation; 1997 Dec; 64(11):1614-7. PubMed ID: 9415569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
    Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
    Snydman DR; Falagas ME; Avery R; Perlino C; Ruthazer R; Freeman R; Rohrer R; Fairchild R; O'Rourke E; Hibberd P; Werner BG
    Transplant Proc; 2001 Jun; 33(4):2571-5. PubMed ID: 11406251
    [No Abstract]   [Full Text] [Related]  

  • 36. [Cytomegalovirus infection in transplant recipients].
    Gondo H
    Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease.
    Snydman DR
    Rev Infect Dis; 1990; 12 Suppl 7():S839-48. PubMed ID: 2173113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
    Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients.
    Zaia JA
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S392-9. PubMed ID: 8274605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.